FXII接触激活产品对αFXIIa具有抑制作用
Li-Chong Xu1, Christopher A Siedlecki1,2
1Department of Surgery, Pennsylvania State University College of Medicine, Hershey, Pennsylvania, USA.
Journal of biomedical materials research. Part A
|September 22, 2023
概括
生物材料对XII因子 (FXII) 的接触激活会产生抑制凝血的抑制剂. 表面特性和prekallikrein影响FXIIa抑制,影响血液凝结级联相互作用.
科学领域:
- 生物化学 生化学
- 材料科学 材料科学 材料科学
- 血液静止 血液静止 血液静止
背景情况:
- 血液凝固的内在途径在与外来表面接触时被激活,例如生物材料.
- 这种接触激活产生酶,启动血凝固.
- 了解这些相互作用对于生物材料的发展和血栓形成的预防至关重要.
研究的目的:
- 调查表面湿度在XII因子 (FXII) 激活和随后的凝血抑制中的作用.
- 为了确定prekallikrein对FXII激活产品及其抑制能力的影响.
- 阐明血蛋白,物质表面和凝固级联之间的复杂相互作用.
主要方法:
- 在缓冲溶液中使用爱水和厌水玻璃珠激活FXII.
- 量化FXII激活产品及其对外源性α-FXIIa (αFXIIa) 的抑制作用.
- 评估Prekallikrein对FXII激活和抑制的影响.
主要成果:
- FXII接触激活产品以度依赖的方式抑制了αFXIIa的促凝活性.
- 抑制率因表面浸湿性而异,在高αFXIIa度 (~39%) 中观察到类似的抑制.
- 普卡利克林在水友表面上增加了FXIIa的产生和调节的抑制剂水平,而激活产品和表面的组合增强了抑制.
结论:
- 生物材料接触激活产生FXII衍生抑制剂,调节凝血.
- 表面的湿透性和prekallikrein的存在显著影响FXII激活产品的抑制能力.
- 这些发现加深了我们对等离子体物质相互作用及其对凝血级联的影响的理解.
相关概念视频
00:46Feedback Inhibition
54.0K
Biochemical reactions are occurring constantly in cells, converting starting substances to different products, usually with the help of enzymes that speed the reactions. Without enzymes, it would take far too long for most reactions to occur to be useful to the cell!
54.0K
01:18Indirect-Acting Cholinergic Agonists: Mechanism of Action
1.9K
Indirect-acting cholinergic agonists work by interacting with an enzyme called acetylcholinesterase (AChE) in the synaptic cleft. They can be reversible or irreversible inhibitors and have different effects on the enzyme.
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex,...
Reversible inhibitors like edrophonium bind to a specific part of the enzyme called the anionic catalytic site. They form noncovalent bonds, which means they are not strongly attached to the enzyme. This creates a temporary and less stable enzyme–inhibitor complex,...
1.9K
01:09GPCRs Regulate Adenylyl Cylase Activity
5.7K
Some GPCRs transmit signals through adenylyl cyclase (AC), a transmembrane enzyme. AC helps synthesize second messenger cyclic adenosine monophosphate (cAMP). AC catalyzes cyclization reaction and converts ATP to cAMP by releasing a pyrophosphate. The pyrophosphate is further hydrolyzed to phosphate by the enzyme pyrophosphatase, which drives cAMP synthesis to completion. However, cAMP is rapidly degraded to 5′ AMP by the enzymes phosphodiesterase (PDE), preventing overstimulation of...
5.7K
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
552
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
552
01:30Combined Effects of Drugs: Antagonism
8.6K
The combined effects of drugs can result in various interactions, of which an important type is antagonism. Antagonism is a mechanism where one drug inhibits or counteracts the effects of another drug. Antagonism can occur through various means, including receptor binding, allosteric modulation, functional interaction, chemical reactions, and pharmacokinetic processes.
The most common type is receptor antagonism, where one drug acts as an antagonist to block the effects of another drug by...
The most common type is receptor antagonism, where one drug acts as an antagonist to block the effects of another drug by...
8.6K
01:29Indirect-Acting Cholinergic Agonists: Chemistry and Structure-Activity Relationship
600
Indirect-acting cholinergic agonists are agents that interact with the acetylcholinesterase enzyme in the synaptic cleft, preventing the breakdown of acetylcholine into choline and acetate. Consequently, the concentration of acetylcholine in the synaptic cleft increases. These agonists can be classified into reversible and irreversible inhibitors based on their duration of action.
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
Reversible inhibitors display short to medium durations of action. Short-acting agents include simple alcohols with...
600